BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 18, 2004
View Archived Issues
CoTherix Prices IPO Low, Raises $30M For Ventavis
Read More
MacroGenics Raises $30M In Second-Round Financing
Read More
ViRexx Enters Agreement To Buy Familiar Firm: AltaRex
Read More
Other News To Note
Read More
Appointments And Advancements
Read More
La Jolla's Riquent Approvable Letter: Finished Study Needed
La Jolla Pharmaceutical Co. received an approvable letter for its lupus drug candidate Riquent that requires the completion of another clinical study for final approval. (BioWorld Today)
Read More
Hardy Attempt' At H&Q-Style Meeting Wins Attendee Praise
Read More